TO · NVCN.TO
Neovasc Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Richmond, BC V6V 2J7
- Website
- neovasc.com
Price · as of 2022-12-31
$40.15
Market cap 110.78M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2008 | $0.00 | $28,144.30 | |||
| 2009 | $0.00 | $0.00 | |||
| 2010 | $0.00 | $0.00 | |||
| 2011 | $0.00 | $0.00 | |||
| 2012 | $187.60 | $0.00 | |||
| 2013 | $0.00 | $0.00 | |||
| 2014 | $0.00 | $0.00 | |||
| 2015 | $0.00 | $10,324.50 | |||
| 2016 | $0.00 | $0.00 | |||
| 2017 | $0.00 | $13,107.10 | |||
| 2018 | $0.00 | $6,026.70 | |||
| 2019 | $0.00 | $0.00 | |||
| 2020 | $0.00 | $0.00 | |||
| 2021 | $0.00 | $0.00 | |||
| 2022 |
AI valuation
Our deep-learning model estimates Neovasc Inc.'s (NVCN.TO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $40.15
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
About Neovasc Inc.
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
- CEO
- Fredericus A. Colen
- Employees
- 49
- Beta
- 2.01
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $40.15) − 1 = — (DCF, example).